Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
Clinical trial NCT06935136 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06935136
- Sponsor
- Ruijin Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-30
- Primary completion
- 2026-10-09
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.